Derniers articles

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Dig Liver Dis

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Ther Adv Med Oncol

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : J Immunother Cancer

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Oncologist

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Int J Mol Sci

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Bull Cancer

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Eur J Cancer

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

AbstractBackground: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Clin Colorectal Cancer

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Cancers

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

AbstractBACKGROUND:Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Br J Surg

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study

AbstractAflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the...

Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Int J Oncol .

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

AbstractPurpose: Human papillomavirus (HPV) is found in 90% of squamous cell carcinomas of the anal canal (SCCA)....

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Clin Cancer Res .

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)

AbstractBackground: 5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for...

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer